Online inquiry

IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13629MR)

This product GTTS-WQ13629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TNFSF4 gene. The antibody can be applied in Allergic asthma, Allergic rhinitis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001297562.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7292
UniProt ID P23510
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13629MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12193MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MORAb-022
GTTS-WQ6767MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DS-1062
GTTS-WQ10853MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M9346A
GTTS-WQ4227MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ9664MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ6185MR IVTScrip™ mRNA-Anti-CD40, CP-870893(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CP-870893
GTTS-WQ9866MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ11984MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW